
Zura Bio fell 74.8% from $3.83 to $0.97, behind the S&P 500's +10.6%. Its worst day was Nov 9 (−69.7%), and its low came Nov 18 at $0.97.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious…
+26.1%, the year's best day · S&P 500 +1.2%
Story events cover the past 12 months · Times ET
Zura Bio closed at its highest level of the year, 83.8% above where the year started.
+1.0% · S&P 500 +0.9%
EPS of $-0.49 missed the $-0.19 estimate on $0.00 revenue.
+2.2% · S&P 500 −0.5%
EPS of $-0.22 missed the $-0.18 estimate on $0.00 revenue.
−7.2% · S&P 500 −0.3%
Zura Bio shares rose 17.8%, while the S&P 500 fell 0.7%.
+17.8% · S&P 500 −0.7%
EPS of $-0.21 missed the $-0.19 estimate on $0.00 revenue.
−1.2% · S&P 500 −0.3%
EPS of $-0.20 beat the $-0.21 estimate on $0.00 revenue.
+19.9% · S&P 500 +0.6%
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16Key secondary endpoints, including HiSCR50 and HiSCR75, were not metBoth doses of
−69.7%, the year's worst day, on 64M shares, the year's heaviest volume · S&P 500 +2.4%
Where it ended: a close of $0.97 on Nov 18, 2026. Up next: Q4 2027 earnings on Mar 18, 2027 (EPS est. $-0.20).
Nothing in the past 12 months.
All ZURA dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ZURA and SPY from Benzinga historical bars. Not investment advice.